SREBF2 and urinary bladder carcinoma: In bladder cancer, a study indicates that SREBP2 interacts with CBP and NFYC-37, activating the transcription of genes involved in the mevalonate pathway, thereby promoting cholesterol biosynthesis and tumor growth (Liu et al., 2023).